Technology transfer / Localization · MENA · Announced 20 May 2026
Biocare Biotech → Dorcas Laboratoires
Algeria's Biocare Biotech and Tunisia's Dorcas Laboratoires signed a strategic MoU in Algiers covering technology transfer and export of insulins made full-process in Algeria.
Parties: Biocare Biotech (Groupe Biocare) (Algeria) → Dorcas Laboratoires (Tunisia)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Algeria (production base) and Tunisia (partner market), with a stated aim of Maghreb integration
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Insulins
- Announced
- 20 May 2026
Our analysis
Why this matters
On 20 May 2026 in Algiers, Groupe BIOCARE, through its subsidiary Biocare Biotech, signed a strategic memorandum of understanding (protocole d'accord) with Tunisia's DORCAS Laboratoires. The agreement covers technology transfer and the export of insulins manufactured full-process in Algeria, with Tunisia as the partner market and a stated aim of Maghreb integration. No financial terms or timelines were published.
The deal fits Algeria's push to turn local insulin production into exports, after years of import substitution.
The full analysis is free to read with a work email on this page.
Source: Esseha